Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Thr-Ala-Pro)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004290 AN007133 Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003565 AN005858 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003179 AN005222 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003036 AN004977 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST003024 AN004958 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 Bacterial cells Pseudomonas aeruginosa Monash Institute of Pharmaceutical Sciences LC-MS
ST002926 AN004798 Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002309 AN003771 Targeting malaria parasites with novel derivatives of azithromycin Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002107 AN003446 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002106 AN003444 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001315 AN002189 Retargeting azithromycin-like compounds as antimalarials with dual modality Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST000546 AN000832 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash University LC-MS
  logo